A mechanistic approach for the scaling of clearance in children.
about
Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic modelStrategic biomarkers for drug development in treating rare diseases and diseases in neonates and infantsApproaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric populationEnvironmental factors, epigenetics, and developmental origin of reproductive disordersThe last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.Getting to 90-90-90 in paediatric HIV: What is needed?Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A.A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3Tips and traps analyzing pediatric PK data.Physiologically based pharmacokinetic modeling and simulation in pediatric drug developmentOndansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndromeEarly Life Metabolism of Bisphenol A: A Systematic Review of the LiteratureMetabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone systemDesigning a Pediatric Study for an Antimalarial Drug by Using Information from AdultsA workflow example of PBPK modeling to support pediatric research and development: case study with lorazepamPhysiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and InfantsDevelopment of a paediatric population-based model of the pharmacokinetics of rivaroxaban.The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Drug Development for Pediatric Populations: Regulatory Aspects.Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance.Knowledge-driven approaches for the guidance of first-in-children dosing.Physiologically based pharmacokinetic (PBPK) modeling in children.An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry.Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Dosage individualization in children: integration of pharmacometrics in clinical practice.Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?Prediction of drug clearance in children: a review of different methodologies.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children.In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.Prehepatic secretion and disposal of insulin in obese adolescents as estimated by three-hour, eight-sample oral glucose tolerance tests.Examining Small Intestinal Transit Time as a Function of Age: Is There Evidence to Support Age-Dependent Differences among Children?
P2860
Q24647832-B724FD43-0323-459A-8259-7533502A7459Q27024346-35A83804-B62C-4747-BF6A-6D2BFD9ECE0CQ28389663-BB983E9A-8C1A-4EEC-BBCF-8D7AB72E6B00Q28397992-4AAF7EBC-14C8-4750-A1B0-77764FDE9965Q30382184-C60EB31B-70EE-4F69-AF3F-3B19025A5BABQ30385352-83B62ED2-153E-4170-B708-5B85468A98C8Q30396069-69848A5D-A9D1-4920-A79A-B0CCFF135C27Q30786488-9EDE1C2C-1D0E-4CED-B0B7-09BB8715C22CQ33574651-2703A7E3-FAC7-4D28-95F4-87DD182D1E9CQ33820152-DA916A8D-8A33-47D5-B635-DD1CAFFCAFD1Q34658074-A4E001CD-7351-4EE2-9922-2D4D11E1C9F2Q35075945-B4947B23-77D0-4016-9367-7F481450DEC0Q35234895-E5B859F2-847A-4EB0-9DCD-860200E8ACD6Q35653564-4A8FB75C-0EB4-4E51-9E60-EF205E75834DQ36307045-BA1C007A-7A24-40CE-A25E-62F7C7616190Q36595721-40BB9C36-82B6-4125-B16A-0C4472EAA9D6Q36644652-DF720C06-512E-4783-AAAB-6E817A1A8253Q36910537-F6D08F4E-E61E-46AD-8B13-7A2927AA05A8Q37008900-97FF4736-F0C9-47BA-813B-40D7D2165C74Q37208505-A1A7672D-284A-4A89-959B-3779E1A0E903Q37470692-A99EF684-E53D-442D-86A4-1FED2E67FB9AQ37492046-E3FEFD53-EFA5-4230-A202-55AD535DB497Q37544540-8139727E-21A9-4233-AEDA-9D23E09AB0A5Q37666706-AEEBDA0F-023D-49D0-8C28-33092771247BQ37781110-6C2E525B-52AA-4B5E-B324-68A3C283D816Q37815555-480D0BAC-255B-4444-87CA-BFA75DBF8E7EQ38016332-3510EF97-BC25-4282-BF6E-9DA534F3E455Q38041230-6EADB59F-C272-4E27-B0DC-119B024747FCQ38047202-3A501F6C-CB29-4C8A-A1E7-DC2D0749DD0AQ38086777-76753F02-42EC-4326-8C40-5EE12506B25BQ38240055-24C0C81F-D23F-4A29-B561-B8CF4F4300C6Q38357598-D85ACDB0-E0C0-4D64-BB39-E84532CA9267Q38367747-D298E62F-C569-44AE-89E5-37062AE532DAQ38527434-67266EFF-4F69-4B3F-ADE3-A793F60BB77EQ38544082-3A8859C4-0521-4F4F-BEDB-44CBB9DAD51FQ38765921-6C2B7F9A-998D-4C11-AA18-11FE6E8AB6BFQ38857191-13E70949-A148-4564-B491-F14240840832Q38972571-9E3E0490-6D43-49E1-B61E-1FC23918AFF0Q39796669-6D5CA354-D651-4E5E-953C-F1F64EFE053CQ39920399-D0739528-814A-406E-BEA6-ACE09B2645B7
P2860
A mechanistic approach for the scaling of clearance in children.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A mechanistic approach for the scaling of clearance in children.
@en
A mechanistic approach for the scaling of clearance in children.
@nl
type
label
A mechanistic approach for the scaling of clearance in children.
@en
A mechanistic approach for the scaling of clearance in children.
@nl
prefLabel
A mechanistic approach for the scaling of clearance in children.
@en
A mechanistic approach for the scaling of clearance in children.
@nl
P2093
P2860
P1476
A mechanistic approach for the scaling of clearance in children.
@en
P2093
Andrea N Edginton
Barbara Voith
Stefan Willmann
P2860
P304
P356
10.2165/00003088-200645070-00004
P577
2006-01-01T00:00:00Z
P6179
1005306347